nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—NEK9—connective tissue—age related macular degeneration	0.00986	0.0285	CbGeAlD
Crizotinib—SIK2—connective tissue—age related macular degeneration	0.00887	0.0257	CbGeAlD
Crizotinib—MAPK7—retina—age related macular degeneration	0.00821	0.0238	CbGeAlD
Crizotinib—EPHA8—eye—age related macular degeneration	0.0082	0.0237	CbGeAlD
Crizotinib—MAPK7—connective tissue—age related macular degeneration	0.00798	0.0231	CbGeAlD
Crizotinib—MET—eye—age related macular degeneration	0.00776	0.0224	CbGeAlD
Crizotinib—MET—retina—age related macular degeneration	0.00769	0.0222	CbGeAlD
Crizotinib—MET—connective tissue—age related macular degeneration	0.00747	0.0216	CbGeAlD
Crizotinib—CDK7—connective tissue—age related macular degeneration	0.00723	0.0209	CbGeAlD
Crizotinib—EPHA3—eye—age related macular degeneration	0.00717	0.0207	CbGeAlD
Crizotinib—ACVR1B—eye—age related macular degeneration	0.00717	0.0207	CbGeAlD
Crizotinib—EPHA3—retina—age related macular degeneration	0.00711	0.0206	CbGeAlD
Crizotinib—JAK3—connective tissue—age related macular degeneration	0.00659	0.0191	CbGeAlD
Crizotinib—STK4—connective tissue—age related macular degeneration	0.00647	0.0187	CbGeAlD
Crizotinib—EPHA5—eye—age related macular degeneration	0.00635	0.0184	CbGeAlD
Crizotinib—EPHA5—retina—age related macular degeneration	0.00629	0.0182	CbGeAlD
Crizotinib—MAP4K1—retina—age related macular degeneration	0.00616	0.0178	CbGeAlD
Crizotinib—ALK—connective tissue—age related macular degeneration	0.00611	0.0177	CbGeAlD
Crizotinib—TYRO3—connective tissue—age related macular degeneration	0.00611	0.0177	CbGeAlD
Crizotinib—IGF1R—eye—age related macular degeneration	0.0061	0.0176	CbGeAlD
Crizotinib—LYN—connective tissue—age related macular degeneration	0.00608	0.0176	CbGeAlD
Crizotinib—STK3—eye—age related macular degeneration	0.00593	0.0172	CbGeAlD
Crizotinib—IGF1R—connective tissue—age related macular degeneration	0.00587	0.017	CbGeAlD
Crizotinib—TESK1—eye—age related macular degeneration	0.00573	0.0166	CbGeAlD
Crizotinib—MERTK—eye—age related macular degeneration	0.00558	0.0161	CbGeAlD
Crizotinib—MERTK—retina—age related macular degeneration	0.00553	0.016	CbGeAlD
Crizotinib—TESK1—connective tissue—age related macular degeneration	0.00552	0.016	CbGeAlD
Crizotinib—ACVR1—eye—age related macular degeneration	0.0054	0.0156	CbGeAlD
Crizotinib—MAP3K12—eye—age related macular degeneration	0.0054	0.0156	CbGeAlD
Crizotinib—ACVR1—retina—age related macular degeneration	0.00535	0.0155	CbGeAlD
Crizotinib—FLT3—connective tissue—age related macular degeneration	0.0052	0.015	CbGeAlD
Crizotinib—ACVR1—connective tissue—age related macular degeneration	0.0052	0.015	CbGeAlD
Crizotinib—BMP2K—connective tissue—age related macular degeneration	0.0049	0.0142	CbGeAlD
Crizotinib—RIPK2—eye—age related macular degeneration	0.00487	0.0141	CbGeAlD
Crizotinib—RIPK2—retina—age related macular degeneration	0.00483	0.014	CbGeAlD
Crizotinib—PTK2B—connective tissue—age related macular degeneration	0.00474	0.0137	CbGeAlD
Crizotinib—RIPK2—connective tissue—age related macular degeneration	0.0047	0.0136	CbGeAlD
Crizotinib—TBK1—eye—age related macular degeneration	0.00453	0.0131	CbGeAlD
Crizotinib—TYK2—eye—age related macular degeneration	0.0045	0.013	CbGeAlD
Crizotinib—TYK2—retina—age related macular degeneration	0.00445	0.0129	CbGeAlD
Crizotinib—MAP3K2—connective tissue—age related macular degeneration	0.00445	0.0129	CbGeAlD
Crizotinib—PTK2—connective tissue—age related macular degeneration	0.00436	0.0126	CbGeAlD
Crizotinib—RPS6KB1—eye—age related macular degeneration	0.00435	0.0126	CbGeAlD
Crizotinib—TYK2—connective tissue—age related macular degeneration	0.00433	0.0125	CbGeAlD
Crizotinib—RPS6KB1—retina—age related macular degeneration	0.00431	0.0125	CbGeAlD
Crizotinib—AXL—eye—age related macular degeneration	0.00431	0.0125	CbGeAlD
Crizotinib—AXL—retina—age related macular degeneration	0.00427	0.0124	CbGeAlD
Crizotinib—RPS6KB1—connective tissue—age related macular degeneration	0.00419	0.0121	CbGeAlD
Crizotinib—AXL—connective tissue—age related macular degeneration	0.00415	0.012	CbGeAlD
Crizotinib—EPHB4—connective tissue—age related macular degeneration	0.00397	0.0115	CbGeAlD
Crizotinib—JAK2—connective tissue—age related macular degeneration	0.00394	0.0114	CbGeAlD
Crizotinib—TEK—connective tissue—age related macular degeneration	0.0038	0.011	CbGeAlD
Crizotinib—YES1—eye—age related macular degeneration	0.00364	0.0105	CbGeAlD
Crizotinib—YES1—retina—age related macular degeneration	0.00361	0.0104	CbGeAlD
Crizotinib—TAOK3—eye—age related macular degeneration	0.00359	0.0104	CbGeAlD
Crizotinib—TAOK3—retina—age related macular degeneration	0.00356	0.0103	CbGeAlD
Crizotinib—YES1—connective tissue—age related macular degeneration	0.00351	0.0101	CbGeAlD
Crizotinib—SRC—eye—age related macular degeneration	0.0035	0.0101	CbGeAlD
Crizotinib—SRC—retina—age related macular degeneration	0.00347	0.01	CbGeAlD
Crizotinib—TAOK3—connective tissue—age related macular degeneration	0.00346	0.01	CbGeAlD
Crizotinib—SRC—connective tissue—age related macular degeneration	0.00337	0.00976	CbGeAlD
Crizotinib—CSF1R—eye—age related macular degeneration	0.00314	0.0091	CbGeAlD
Crizotinib—CSF1R—connective tissue—age related macular degeneration	0.00303	0.00876	CbGeAlD
Crizotinib—ABL1—eye—age related macular degeneration	0.00249	0.00719	CbGeAlD
Crizotinib—ABL1—retina—age related macular degeneration	0.00246	0.00712	CbGeAlD
Crizotinib—ABL1—connective tissue—age related macular degeneration	0.00239	0.00693	CbGeAlD
Crizotinib—ABCB1—retina—age related macular degeneration	0.000766	0.00222	CbGeAlD
Crizotinib—LYN—Adaptive Immune System—CD36—age related macular degeneration	6.97e-05	0.000107	CbGpPWpGaD
Crizotinib—JAK2—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	6.97e-05	0.000107	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—C3—age related macular degeneration	6.97e-05	0.000106	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—SQSTM1—age related macular degeneration	6.96e-05	0.000106	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—C3—age related macular degeneration	6.94e-05	0.000106	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—CCL2—age related macular degeneration	6.9e-05	0.000105	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—C3—age related macular degeneration	6.88e-05	0.000105	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—C3—age related macular degeneration	6.85e-05	0.000105	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—C3—age related macular degeneration	6.84e-05	0.000105	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—C3—age related macular degeneration	6.82e-05	0.000104	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—CD36—age related macular degeneration	6.79e-05	0.000104	CbGpPWpGaD
Crizotinib—TYK2—Axon guidance—VEGFA—age related macular degeneration	6.77e-05	0.000104	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NMNAT1—age related macular degeneration	6.71e-05	0.000103	CbGpPWpGaD
Crizotinib—JAK2—Disease—CST3—age related macular degeneration	6.69e-05	0.000102	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ABCA4—age related macular degeneration	6.68e-05	0.000102	CbGpPWpGaD
Crizotinib—BLK—Immune System—C3—age related macular degeneration	6.68e-05	0.000102	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—CCL2—age related macular degeneration	6.67e-05	0.000102	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—SQSTM1—age related macular degeneration	6.67e-05	0.000102	CbGpPWpGaD
Crizotinib—FGR—Immune System—C3—age related macular degeneration	6.66e-05	0.000102	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—KDR—age related macular degeneration	6.65e-05	0.000102	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—CD36—age related macular degeneration	6.61e-05	0.000101	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—C3—age related macular degeneration	6.61e-05	0.000101	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CRP—age related macular degeneration	6.61e-05	0.000101	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RHO—age related macular degeneration	6.57e-05	0.0001	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—CRP—age related macular degeneration	6.54e-05	0.0001	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—CRP—age related macular degeneration	6.51e-05	9.95e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CRP—age related macular degeneration	6.51e-05	9.95e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—APOE—age related macular degeneration	6.49e-05	9.91e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—SQSTM1—age related macular degeneration	6.46e-05	9.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—C3—age related macular degeneration	6.44e-05	9.84e-05	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—VEGFA—age related macular degeneration	6.38e-05	9.75e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—CRP—age related macular degeneration	6.35e-05	9.71e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—KDR—age related macular degeneration	6.35e-05	9.71e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—APOE—age related macular degeneration	6.35e-05	9.7e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—TLR4—age related macular degeneration	6.33e-05	9.68e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—CRP—age related macular degeneration	6.33e-05	9.68e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—SQSTM1—age related macular degeneration	6.31e-05	9.64e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—SQSTM1—age related macular degeneration	6.28e-05	9.59e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—TLR4—age related macular degeneration	6.27e-05	9.59e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—SLC16A8—age related macular degeneration	6.27e-05	9.58e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—APOE—age related macular degeneration	6.26e-05	9.56e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—TLR4—age related macular degeneration	6.24e-05	9.54e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—TLR4—age related macular degeneration	6.24e-05	9.54e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—KDR—age related macular degeneration	6.22e-05	9.5e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—CRP—age related macular degeneration	6.12e-05	9.36e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFBR1—age related macular degeneration	6.12e-05	9.35e-05	CbGpPWpGaD
Crizotinib—LCK—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	6.11e-05	9.33e-05	CbGpPWpGaD
Crizotinib—SRC—Focal Adhesion—VEGFA—age related macular degeneration	6.1e-05	9.32e-05	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—VEGFA—age related macular degeneration	6.09e-05	9.31e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—TLR4—age related macular degeneration	6.09e-05	9.31e-05	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	6.07e-05	9.28e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—TLR4—age related macular degeneration	6.07e-05	9.28e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFBR1—age related macular degeneration	6.03e-05	9.22e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—CCL2—age related macular degeneration	6.03e-05	9.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFBR1—age related macular degeneration	6.01e-05	9.19e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—CD36—age related macular degeneration	5.96e-05	9.12e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CD36—age related macular degeneration	5.95e-05	9.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—SQSTM1—age related macular degeneration	5.9e-05	9.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—TLR4—age related macular degeneration	5.87e-05	8.97e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ELOVL4—age related macular degeneration	5.87e-05	8.97e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CST3—age related macular degeneration	5.86e-05	8.96e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—CD36—age related macular degeneration	5.85e-05	8.94e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RHO—age related macular degeneration	5.81e-05	8.88e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD36—age related macular degeneration	5.75e-05	8.79e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFBR1—age related macular degeneration	5.72e-05	8.74e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD36—age related macular degeneration	5.71e-05	8.73e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD36—age related macular degeneration	5.67e-05	8.67e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—C3—age related macular degeneration	5.64e-05	8.62e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFBR1—age related macular degeneration	5.55e-05	8.49e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SQSTM1—age related macular degeneration	5.55e-05	8.47e-05	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—VEGFA—age related macular degeneration	5.48e-05	8.38e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SQSTM1—age related macular degeneration	5.47e-05	8.36e-05	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—VEGFA—age related macular degeneration	5.46e-05	8.34e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—CCL2—age related macular degeneration	5.45e-05	8.33e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—C3—age related macular degeneration	5.45e-05	8.33e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—C3—age related macular degeneration	5.41e-05	8.28e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—C3—age related macular degeneration	5.41e-05	8.27e-05	CbGpPWpGaD
Crizotinib—SRC—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	5.4e-05	8.26e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD36—age related macular degeneration	5.38e-05	8.22e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—C3—age related macular degeneration	5.37e-05	8.21e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CRP—age related macular degeneration	5.36e-05	8.2e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—CCL2—age related macular degeneration	5.33e-05	8.15e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—VEGFA—age related macular degeneration	5.32e-05	8.13e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CD36—age related macular degeneration	5.27e-05	8.05e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFBR1—age related macular degeneration	5.26e-05	8.05e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—VEGFA—age related macular degeneration	5.25e-05	8.02e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—VEGFA—age related macular degeneration	5.22e-05	7.98e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD36—age related macular degeneration	5.22e-05	7.98e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CST3—age related macular degeneration	5.19e-05	7.93e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SQSTM1—age related macular degeneration	5.19e-05	7.93e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CRP—age related macular degeneration	5.18e-05	7.92e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—SQSTM1—age related macular degeneration	5.17e-05	7.9e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—KDR—age related macular degeneration	5.16e-05	7.88e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—VEGFA—age related macular degeneration	5.15e-05	7.87e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—TLR4—age related macular degeneration	5.14e-05	7.86e-05	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—VEGFA—age related macular degeneration	5.13e-05	7.84e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CRP—age related macular degeneration	5.11e-05	7.81e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—VEGFA—age related macular degeneration	5.11e-05	7.81e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—VEGFA—age related macular degeneration	5.11e-05	7.81e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—C3—age related macular degeneration	5.1e-05	7.79e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD36—age related macular degeneration	5.06e-05	7.73e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—C3—age related macular degeneration	5.04e-05	7.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SQSTM1—age related macular degeneration	5.04e-05	7.7e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—C3—age related macular degeneration	4.99e-05	7.63e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—CETP—age related macular degeneration	4.99e-05	7.62e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—TLR4—age related macular degeneration	4.97e-05	7.59e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—C3—age related macular degeneration	4.95e-05	7.56e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—TLR4—age related macular degeneration	4.9e-05	7.49e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CRP—age related macular degeneration	4.85e-05	7.41e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—VEGFA—age related macular degeneration	4.84e-05	7.4e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—VEGFA—age related macular degeneration	4.83e-05	7.39e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—C3—age related macular degeneration	4.79e-05	7.33e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CRP—age related macular degeneration	4.75e-05	7.26e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC16A8—age related macular degeneration	4.73e-05	7.23e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CRP—age related macular degeneration	4.71e-05	7.19e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—APOE—age related macular degeneration	4.69e-05	7.17e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFBR1—age related macular degeneration	4.66e-05	7.12e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—TLR4—age related macular degeneration	4.65e-05	7.1e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KDR—age related macular degeneration	4.59e-05	7.02e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—SQSTM1—age related macular degeneration	4.58e-05	6.99e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—TLR4—age related macular degeneration	4.55e-05	6.96e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—C3—age related macular degeneration	4.52e-05	6.91e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—TLR4—age related macular degeneration	4.51e-05	6.9e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFBR1—age related macular degeneration	4.5e-05	6.87e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—C3—age related macular degeneration	4.49e-05	6.86e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—VEGFA—age related macular degeneration	4.43e-05	6.77e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—C3—age related macular degeneration	4.42e-05	6.76e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—APOE—age related macular degeneration	4.25e-05	6.5e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—CCL2—age related macular degeneration	4.24e-05	6.48e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—C3—age related macular degeneration	4.23e-05	6.47e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD36—age related macular degeneration	4.23e-05	6.46e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFBR1—age related macular degeneration	4.21e-05	6.43e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD36—age related macular degeneration	4.21e-05	6.43e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—APOE—age related macular degeneration	4.18e-05	6.39e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NMNAT1—age related macular degeneration	4.13e-05	6.32e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—APOE—age related macular degeneration	4.12e-05	6.29e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—C3—age related macular degeneration	4.11e-05	6.27e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—C3—age related macular degeneration	4.1e-05	6.27e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KDR—age related macular degeneration	4.09e-05	6.26e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SQSTM1—age related macular degeneration	4.08e-05	6.23e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KDR—age related macular degeneration	4.04e-05	6.17e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—C3—age related macular degeneration	4.01e-05	6.12e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—C3—age related macular degeneration	3.99e-05	6.09e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—VEGFA—age related macular degeneration	3.98e-05	6.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD36—age related macular degeneration	3.96e-05	6.05e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—APOE—age related macular degeneration	3.94e-05	6.02e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CCL2—age related macular degeneration	3.94e-05	6.02e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—VEGFA—age related macular degeneration	3.91e-05	5.98e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—VEGFA—age related macular degeneration	3.9e-05	5.95e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—VEGFA—age related macular degeneration	3.87e-05	5.92e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KDR—age related macular degeneration	3.86e-05	5.9e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—VEGFA—age related macular degeneration	3.84e-05	5.87e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—APOE—age related macular degeneration	3.82e-05	5.84e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—VEGFA—age related macular degeneration	3.82e-05	5.84e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SQSTM1—age related macular degeneration	3.82e-05	5.83e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CRP—age related macular degeneration	3.81e-05	5.83e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CRP—age related macular degeneration	3.79e-05	5.8e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—C3—age related macular degeneration	3.75e-05	5.73e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KDR—age related macular degeneration	3.74e-05	5.72e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFBR1—age related macular degeneration	3.69e-05	5.63e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—VEGFA—age related macular degeneration	3.66e-05	5.6e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—TLR4—age related macular degeneration	3.65e-05	5.58e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—TLR4—age related macular degeneration	3.64e-05	5.56e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ELOVL4—age related macular degeneration	3.61e-05	5.52e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	3.59e-05	5.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—VEGFA—age related macular degeneration	3.59e-05	5.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CRP—age related macular degeneration	3.57e-05	5.45e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—C3—age related macular degeneration	3.52e-05	5.38e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CCL2—age related macular degeneration	3.51e-05	5.37e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—VEGFA—age related macular degeneration	3.5e-05	5.35e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—C3—age related macular degeneration	3.47e-05	5.31e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD36—age related macular degeneration	3.47e-05	5.3e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CCL2—age related macular degeneration	3.46e-05	5.29e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—VEGFA—age related macular degeneration	3.43e-05	5.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—TLR4—age related macular degeneration	3.42e-05	5.23e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SQSTM1—age related macular degeneration	3.34e-05	5.11e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCL2—age related macular degeneration	3.31e-05	5.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—C3—age related macular degeneration	3.3e-05	5.04e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—C3—age related macular degeneration	3.28e-05	5.02e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—APOE—age related macular degeneration	3.28e-05	5.01e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFBR1—age related macular degeneration	3.26e-05	4.99e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—APOE—age related macular degeneration	3.23e-05	4.94e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—APOE—age related macular degeneration	3.22e-05	4.93e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCL2—age related macular degeneration	3.21e-05	4.91e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KDR—age related macular degeneration	3.21e-05	4.91e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CCL2—age related macular degeneration	3.21e-05	4.91e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—LIPC—age related macular degeneration	3.21e-05	4.9e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—C3—age related macular degeneration	3.2e-05	4.89e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KDR—age related macular degeneration	3.17e-05	4.84e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—VEGFA—age related macular degeneration	3.15e-05	4.81e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CRP—age related macular degeneration	3.12e-05	4.77e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CETP—age related macular degeneration	3.09e-05	4.73e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD36—age related macular degeneration	3.07e-05	4.69e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—APOE—age related macular degeneration	3.07e-05	4.69e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KDR—age related macular degeneration	3.01e-05	4.59e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—TLR4—age related macular degeneration	3e-05	4.58e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—APOE—age related macular degeneration	2.98e-05	4.55e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SQSTM1—age related macular degeneration	2.96e-05	4.52e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KDR—age related macular degeneration	2.92e-05	4.46e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC16A8—age related macular degeneration	2.91e-05	4.45e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—C3—age related macular degeneration	2.91e-05	4.44e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—VEGFA—age related macular degeneration	2.84e-05	4.34e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—APOE—age related macular degeneration	2.82e-05	4.31e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—VEGFA—age related macular degeneration	2.79e-05	4.26e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CRP—age related macular degeneration	2.77e-05	4.23e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCL2—age related macular degeneration	2.76e-05	4.21e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCL2—age related macular degeneration	2.72e-05	4.15e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—TLR4—age related macular degeneration	2.65e-05	4.05e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—C3—age related macular degeneration	2.59e-05	3.96e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCL2—age related macular degeneration	2.58e-05	3.94e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VEGFA—age related macular degeneration	2.53e-05	3.87e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCL2—age related macular degeneration	2.5e-05	3.83e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—APOE—age related macular degeneration	2.5e-05	3.82e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—C3—age related macular degeneration	2.42e-05	3.7e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—LIPC—age related macular degeneration	2.42e-05	3.7e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—APOE—age related macular degeneration	2.41e-05	3.69e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KDR—age related macular degeneration	2.36e-05	3.61e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CETP—age related macular degeneration	2.34e-05	3.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—APOE—age related macular degeneration	2.26e-05	3.45e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—age related macular degeneration	2.26e-05	3.45e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—age related macular degeneration	2.22e-05	3.4e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KDR—age related macular degeneration	2.21e-05	3.38e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—age related macular degeneration	2.13e-05	3.25e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—C3—age related macular degeneration	2.12e-05	3.24e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—age related macular degeneration	2.06e-05	3.15e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL2—age related macular degeneration	2.03e-05	3.1e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APOE—age related macular degeneration	1.98e-05	3.02e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KDR—age related macular degeneration	1.94e-05	2.96e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL2—age related macular degeneration	1.9e-05	2.9e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—C3—age related macular degeneration	1.88e-05	2.87e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CD36—age related macular degeneration	1.86e-05	2.84e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—age related macular degeneration	1.77e-05	2.71e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOE—age related macular degeneration	1.75e-05	2.67e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—age related macular degeneration	1.75e-05	2.67e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KDR—age related macular degeneration	1.71e-05	2.62e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—age related macular degeneration	1.66e-05	2.54e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—age related macular degeneration	1.66e-05	2.53e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—age related macular degeneration	1.64e-05	2.51e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—age related macular degeneration	1.61e-05	2.46e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LIPC—age related macular degeneration	1.49e-05	2.28e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—age related macular degeneration	1.47e-05	2.25e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CETP—age related macular degeneration	1.44e-05	2.2e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CD36—age related macular degeneration	1.4e-05	2.14e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—age related macular degeneration	1.3e-05	1.99e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—age related macular degeneration	1.24e-05	1.89e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—age related macular degeneration	1.22e-05	1.86e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—age related macular degeneration	1.07e-05	1.63e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—age related macular degeneration	9.45e-06	1.44e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CD36—age related macular degeneration	8.65e-06	1.32e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—age related macular degeneration	7.63e-06	1.17e-05	CbGpPWpGaD
